Your session is about to expire
← Back to Search
Stem Cell Transplant for Sickle Cell Disease
Study Summary
This trial will test whether a stem cell transplant can be a safe and effective treatment for sickle cell disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is severely impaired.My heart's pumping ability is reduced, or I have high blood pressure in the lungs.I have acute hepatitis or severe liver damage, confirmed by a biopsy.I am between 2 and 25 years old.I have a family member who is a partial match and has normal or sickle trait blood.I have a specific type of sickle cell disease.I have severe sickle cell disease with complications like stroke, acute chest syndrome, or organ damage.My oxygen levels are low or my lungs struggle to transfer oxygen into my blood.I need assistance with my daily activities.
- Group 1: Stage I
- Group 2: Stage II
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been enrolled in this clinical research?
"Absolutely correct. The clinicaltrials.gov website confirms that recruitment for this study is still ongoing, having been first posted on October 1st 2022 and recently updated on May 13th 2022. 38 participants are needed from a single trial site."
What qualifications must one fulfill to participate in this research effort?
"This study is seeking 38 participants who are between two and 25 years old and have anemia, sickle cell. Eligible patients must meet the following criteria: Hemoglobin SS, SC, S-β0 Thalassemia or SO-Arab Sickle Cell Disease; Age within Stage 1 (10 to 25) or Stage II (2 to 25); Lack of a fully matched family donor in National Marrow Donor Program register; Partially-matched family member with hemoglobin AA/AS phenotype; Severe Phenotype as evidenced by Neurologic manifestations of sickle disease including CVA/TIA or abnormal MRI findings suggestive of"
Does this research project accept participants aged 18 and above?
"Following the rules for participation, participants must range in age from 2 to 25 years old."
Are there vacancies in this medical trial for volunteers?
"Per the records found on clinicaltrials.gov, this study is actively looking to recruit participants. The trial was inaugurated October 1st 2022 and has since been amended May 13th of the same year."
Share this study with friends
Copy Link
Messenger